Corbus Pharmaceuticals Holdings, Inc. · NASDAQ:CRBP

Corbus Pharmaceuticals — Investor Presentation (August 2023)

46 slides from Corbus Pharmaceuticals's investor presentation, Aug 3, 2023

  1. Slide 1: Connecting Innovation to Purpose: Corporate Presentation August 2023

    Connecting Innovation to Purpose Corporate Presentation August 2023 NASDAQ: CRBP • CorbusPharma.com • @CorbusPharma Exhibit 99.1

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements This presentation contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Co

  3. Slide 3: Introducing the new Corbus Pharmaceuticals

    Introducing the new Corbus Pharmaceuticals Norwood, MA (Boston area) NASDAQ: CRBP Precision oncology + differentiated assets Established targets  enhance probability of success Multiple catalysts in 2023 – 2024

  4. Slide 4: Diversified pipeline with differentiated clinical risk profiles

    Next Generation Nectin-4 targeting ADC CRB-701 Next generation Nectin-4 targeting ADC Nectin-4 positive solid tumors CSPC (China) Dose Escalation Started Q1 2023 Ends Q4 2023 Dose Confirmation / Expansion Start Q1 2024 Dose Confirmation / Expansion Start Q1 2024 Corbus (US + Europe) Dose Escalation

  5. Slide 5: CRB-701 Next Gen Nectin-4 Targeting ADC

    CRB-701 Next Gen Nectin-4 Targeting ADC

  6. Slide 6: CRB-701: Key clinical updates

    CRB-701: Key clinical updates Clinical Progress Clinical Data Current China Phase 1 escalation is ahead of schedule (ends Q4 2023) CRB-701: 1.2 mg/kg (Q3W/21 days) vs. PADCEV®: 1.25 mg/kg (Q1Wx3/28 days)  ADC AUC is comparable CRB-701 is currently dosing above PADCEV®’s RP2D of 1.25 mg/kg Marked re

  7. Slide 7: CRB-701: next generation site-specific Nectin-4 targeting ADC

    CRB-701: next generation site-specific Nectin-4 targeting ADC MMAE = Monomethyl auristatin E ADCC = antibody-dependent cellular cytotoxicity CDC = complement dependent cytotoxicity DAR = Drug Antibody Ratio Source(s): Corbus data on file; PADCEV®; BLA 761137; Tong et al. An Insight into FDA Approved

  8. Slide 8: CRB-701: Potential to improve tolerability + response duration

    CRB-701: Potential to improve tolerability + response duration Source(s): Modified image from Corbus data on file; Corbus data on file Longer t½ ADC Faster ADC internalization Improved linker stability Optimized DAR Enhanced ADC homogeneity Increased ADC hydrophilicity Reduction of free-MMAE Opportu

  9. Slide 9: Nectin-4 landscape is emergent and diverse

    Nectin- 4 / payload IND enabling Phase 1 Phase 2 Phase 3 Approved Nectin-4 landscape is emergent and diverse ADC Non-ADC (bicycle drug conjugate) MMAE ADC Non-MMAE * Eli Lilly purchased Emergence Therapeutics on June 29th 2023 for a estimated total of $470M with an additional $335M in future milesto

  10. Slide 10: Multiple pathways to regulatory approval are available to CRB-701

    Multiple pathways to regulatory approval are available to CRB-701 CRB-701 mUC POC exists New indications Frontline mUC Post-PADCEV® Improved monotherapy Novel combinations First in class Accelerated pathway Opportunity to apply a proprietary companion diagnostic to increase POS

  11. Slide 11: CRB-701: Once in 21 days schedule offers significant advantages

    CRB-701: Once in 21 days schedule offers significant advantages The current dosing schedule suggests 3 doses of PADCEV® compared to 1 dose CRB-701 PADCEV® CRB-701 Patient / physician convenience Combination flexibility Clinical cycle comparison Source(s): Corbus data on file; PADCEV® Prescribing Inf

  12. Slide 12: PADCEV projected to reach up to ~$5B in global sales

    PADCEV® projected to reach up to ~$5B in global sales by 2028 Late-stage Clinical Development $5B 1Projected revenues for UC/Bladder only ® Phase 1 Phase 2 Phase 3 1L untreated locally advanced or metastatic urothelial cancer + pembrolizumab Perioperative muscle invasive bladder cancer + pembrolizum

  13. Slide 13: PADCEV safety limitations impact tolerability and dose intensity

    PADCEV® safety limitations impact tolerability and dose intensity PADCEV® monotherapy1 PADCEV® + pembrolizumab2 All Grades ≥ Gr 3 All Grades ≥ Gr 3 Skin Reactions 56% 12% 72% 20% Peripheral Neuropathy 53% 5% 65% 3.3%* PADCEV® Adverse Events (% of patients) Source(s): 1. PADCEV® Prescribing Informati

  14. Slide 14: PADCEV (EV-101) incidence of TRAEs

    PADCEV® (EV-101)1 Incidence of TRAEs That Occurred in 20% of Patients Adverse Reactions (≥30%) in Patients Treated with PADCEV® in EV-301 0.75 mg/kg N = 14 1.0 mg/kg N = 27 1.25 mg/kg* N = 112 @RP2D of 1.25 mg/kg PADCEV®  increased frequency of TRAEs* Objective Response Rate1 All grade TRAEs1 ≥Gr 3

  15. Slide 15: Current understanding of PADCEV monotherapy experience in mUC

    Current understanding of PADCEV® monotherapy experience in mUC ® Duration of Response ~5 months 47% Rate of Serious Adverse Events (SAEs) 61% Dose interruptions 34% Dose reductions 17% Dose Discontinuations Revised: 4/2023 PADCEV® Prescribing Information Source(s): PADCEV® Prescribing Information as

  16. Slide 16: CRB-701: equivalent pre-clinical efficacy in DAR 2 vs. DAR 4 ADC-MMAE

    CRB-701: equivalent pre-clinical efficacy in a DAR 2 vs. DAR 4 ADC-MMAE Comparison of in-vivo pharmacology Prostate Cancer Triple Negative Breast Cancer P *** 0.001; ** 0.01; * 0.1 If improved therapeutic index is demonstrated clinically then the potential to see both a higher dose & greater efficac

  17. Slide 17: CRB-701: preferentially delivers the payload MMAE to the tumor xenograft

    CRB-701: preferentially delivers the payload MMAE to the tumor xenograft Breast cancer xenograft MDA-MB-468 pharmacokinetics Tumor specific release of the MMAE payload Supports improved efficacy and therapeutic index Measurement Tumor Cmax Serum Cmax Tumor/ Serum AUC ratio* CRB-701 ug/ml 8.3 76.4 0.

  18. Slide 18: Pre-clinical PK: long half-life, high ADC exposure, low free-MMAE

    Half Life (t1/2) days* Total ADC in plasma Single dose PK in Non-human Primates  ~2.8X  ~4.5X  ~3.5X Cmax  ~1.6X mg/mL h*mg/mL pg/mL h*pg/mL AUC (0-7days) AUC Pre-clinical data: CRB-701 demonstrates a long half-life with high ADC exposure + low free-MMAE compared to PADCEV® CRB-701 PADCEV® 6 mg/

  19. Slide 19: Hypothesis: reducing free-MMAE exposure reduces dose limiting adverse events

    Hypothesis: reducing free-MMAE exposure will be associated with a reduction of dose limiting adverse events for CRB-701 Source(s): EPAR PADCEV® Feb, 2022. European Public Assessment Report (EPAR) …

  20. Slide 20: Hypothesis: free MMAE levels define a key safety threshold

    Hypothesis: free MMAE levels @ 1 mg/kg PADCEV® defines a key safety threshold Free-MMAE Source: Rosenberg J. EV-101: A Phase I Study of Single-Agent Enfortumab Vedotin in Patients With Nectin-4-Positive Solid Tumors, Including Metastatic Urothelial Carcinoma. J Clin Oncol. 2020 Apr 1;38(10):1041-104

  21. Slide 21: Clinical data: similar ADC levels with 6-fold lower free-MMAE than PADCEV

    Half Life (t1/2) days Total ADC in plasma Single dose PK in Humans (cross trial data represented) Cmax ng/mL day*ng/mL AUC Clinical data: At similar drug doses CRB-701 delivers similar ADC levels but with 6-fold lower free-MMAE than PADCEV® CRB-701 1.2 mg/kg (D1 over 21 days) PADCEV® 1.25 mg/kg (D1,

  22. Slide 22: CRB-701 escalation is ongoing, already at higher doses than PADCEV

    CRB-701 Escalation is ongoing —> already at higher doses than PADCEV® 22 DL-5 DL-1 No DLT DL-2 No DLT 1.2 mg/kg No DLT DL-4 No DLT DL-6 0.5 mg/kg 0.75 mg/kg 1 mg/kg 1.25 mg/kg Recruiting NOW RP2D CRB-701 PADCEV® PADCEV® free-MMAE exposures @ 1.0 mg/kg Cmax 2.6 ng/mL AUC0-7 13 day*ng/mL AUC0-21 39 da

  23. Slide 23: Validation of Nectin-4 as a tumor associated antigen beyond mUC

    Validation of Nectin-4 as a tumor associated antigen beyond mUC Parameter Patients (N=46) Confirmed ORR 11 (23.9%) CR 1 (2.2%) PR 10 (21.7%) SD 15 (32.6%) mPFS 3.94 months Source: Corbus data on file, Swiecicki et al., Abstract 6017., ASCO 2023 Elevated Nectin-4 expression: urothelial, breast, ovari

  24. Slide 24: Corbus in silico analysis points to tumors outside current competition

    Corbus in silico analysis points to specific tumors outside current competition Source(s): Corbus proprietary analysis: Log2 fold change of nectin-4 expression as a ratio to normal tissue Differentiation of CRB-701’s approach Selecting tumors with a strong differential Nectin-4 gene expression Compa

  25. Slide 25: Nonclinical / Clinical Development plan

    Clinical Status: Nonclinical / Clinical Development plan 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1 2025 Q2 2025 Q3 CRB-701 Development Timeline China US/EU Non-clinical TAA validation of Nectin-4 US RP2D Escalation (6 step) Nectin-4 – ADCC / CDC & TIGIT ligand Nonclinic

  26. Slide 26: CRB-601 Potential best-in-class avb8 mAb

    CRB-601 Potential “best-in-class” ⍺vβ8 mAb

  27. Slide 27: CRB-601 has the potential to enhance checkpoint inhibition

    CRB-601 has the potential to enhance checkpoint inhibition Focus on adopting a precision-targeted approach Novel mechanism to target TGFb in the tumor microenvironment Large opportunity potential if POC is validated

  28. Slide 28: Targeting integrin avb8 is a novel approach to regulating TGFβ

    Targeting the integrin ⍺vβ8 represents a novel approach to regulating TGFβ Source(s): Huang et al., 2021. Recent progress in TGFβ inhibitors for cancer therapy.

  29. Slide 29: CRB-601 targets latent-TGFβ by blocking integrin avb8

    CRB-601 is targeting latent -TGFβ by blocking the integrin avb8 The integrin avb8 is expressed in the tumor microenvironment (TME) Latent-TGFb is also expressed in the TME CRB-601 is a blocking antibody preventing the interaction of these two proteins

  30. Slide 30: mAbs targeting TGFβ activation are advancing clinically

    mAbs targeting TGFβ activation are advancing clinically Source(s): Company websites. Clinicaltrials.gov. Internal analysis. CRB-601 PF-06940434 SRK-181 ABBV-151 RG6440 MOA ⍺vβ8 ⍺vβ8 L-TGFβ GARP (TGFβ1) L-TGFβ Clinical Stage IND in Q4 2023 Phase 1/2 updated July 2023 Phase 1 Phase 2 updated July 2023

  31. Slide 31: CRB-601 Next Steps

    CRB-601 Next Steps IND filing scheduled for H2-2023 FPI expected H1-2024 Non-clinical validation of a potential patient selection biomarker in 2023 Dose escalation and confirmation will be the focus through 2024

  32. Slide 32: Upcoming catalysts, Leadership, Financials

    Upcoming catalysts Leadership Financials

  33. Slide 33: 2023 - 2024 Catalysts

    2023 - 2024 Catalysts 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 CRB - 601 ⍺vβ8 mAb CRB - 701 Nectin-4 targeting ADC IND FPI AACR-NCI-EORTC TGFβ Summit NYAS ESMO ASCO Trials in Progress Conference presentation Clinical milestone SITC PK = pharmacokinetics CDx = companion diagnos

  34. Slide 34: Management Team

    Management Team Yuval Cohen, PhD Chief Executive Officer, Director Corbus co-founder and Chief Executive Officer since 2014. Previously the President and co-founder of Celsus Therapeutics from 2005 Sean Moran, CPA, MBA Chief Financial Officer Corbus co-founder and Chief Financial Officer since 2014. P

  35. Slide 35: Board of Directors

    Board of Directors Amb. Alan Holmer Ret. Chairman of the Board More than two decades of public service in Washington, D.C. including Special Envoy to China; Former CEO of PhRMA Avery W. (Chip) Catlin Director More than 25 years of senior financial leadership experience in life science companies; Form

  36. Slide 36: Investment Summary

    Investment Summary Advancing anti-⍺vβ8 integrin program to IND submission in Q4-2023 Engaging in business development activities to expand Corbus oncology pipeline Sufficient capital to fund operations through the second quarter of 2024 CRBP Ticker $37 Million Focus on developing precision oncology

  37. Slide 37: Appendix

    Appendix

  38. Slide 38: CRB-701 is licensed from CSPC, a top ten biopharmaceutical company in China

    CRB-701 is licenced from CSPC1: a top ten biopharmaceutical company in China2 HKSE: 1093.HK Market Cap: $10.8B3 2022 Revenue: $4.3B3 # of employees: 24,837 864 drug licenses, 68 API licenses ~300 R&D projects under development, First approval in China for mRNA covid vaccine Therapeutic out licensing

  39. Slide 39: TGFβ predicts poor clinical outcomes in a subset of cancer patients

    TGFβ predicts poor clinical outcomes in a subset of cancer patients 0 25 20 15 10 5 0.0 0.2 0.4 0.6 0.8 1.0 N = 8,461 cancers, multiple cell types Time (years) Overall survival, % Immunogenomic subtypes in cancer Source(s): Thorsson, et al. The Immune Landscape of Cancer, Immunity. 2018; 48:817 C1 C

  40. Slide 40: Significant opportunity in improving response to PD-1/L1

    Significant opportunity in improving response to PD-1 /L1’s 70 - 80% of patients do not respond to PD-1/L1 therapy1 $70B+ in projected PD-1/L1 sales worldwide by 20282 Opportunity to improve response with biomarker-based, precision combos Source(s): Sun, JY., Zhang, D., Wu, S. et al. Resistance to P

  41. Slide 41: TGF-β signaling has a negative association with PD-L1 inhibitor responses

    TGF-β signaling has a negative association with PD-L1 inhibitor responses clinically Source(s): Sun, JY., Zhang, D., Wu, S. et al. Resistance to PD-1/PD-L1 blockade cancer immunotherapy: mechanisms, predictive factors, and future perspectives. Biomark Res 8, 35 (2020). Evaluate, January 2023 Clinica

  42. Slide 42: CRB-601 enhances anti-PD-1 therapy in murine tumor models

    CRB-601 enhances anti-PD-1 therapy in checkpoint inhibition sensitive and resistant murine tumor models CRB-601: 10 mg/kg BIW Anti-PD-1: 10 mg/kg BIW 10 animals / group Animals randomized at 50-80 mm3 Comparisons across arms *p<0.05, ***p<0.001, ****p<0.0001 % TGI MC38 EMT6 4T1 Anti-PD-1 54 -8 6 CRB

  43. Slide 43: avb8 blockade with anti-PD-1 increased TIL populations in EMT6 tumors

    Blockade of ⍺vβ8 in combination with anti-PD-1 increased TIL populations in immune excluded EMT6 tumors **** *** **** **** **** *** **** **** Ki67+CD4 T Cells Ki67+CD8 T Cells CD4 T Cells CD8 T Cells Tumor Size * *** * **** ** *** ** *** ** **** * **** * Treatment Days -14 0 3 6 10 Anti-PD-1, 10 mg/

  44. Slide 44: CRB-601 reshapes effector T and NK cells in MC38 tumors

    CRB-601 Reshapes the landscape of effector T and NK cells in MC38 tumors Source(s): Corbus data on file

  45. Slide 45: Proprietary algorithm to define the clinical focus for CRB-601

    Applying a proprietary algorithm to define the clinical focus for CRB-601 A multi-parametric, immune-focused algorithm has refined indications for CRB-601 The combination of immune features and gene expression profiles have identified 9 indications for clinical priority High Low Quartiles Source(s):

  46. Slide 46: Patient selection strategies will enhance the probability of success

    Patient selection strategies will enhance the probability of success Source(s): Corbus proprietary analysis: Log2 fold change of nectin-4 expression as a ratio to normal tissue Controls Ovarian Melanoma Breast Colon Prioritization of indications with differential gene expression vs. normal tissues w

Corbus Pharmaceuticals Holdings — Investor Presentation (August 2023) on 6ix